| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596190 | FENNEC PHARMS INC | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
Jan, 2038
(13 years from now) | |
| US11510984 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
| US11291728 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
| US11617793 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(15 years from now) | |
Pedmark is owned by Fennec Pharms Inc.
Pedmark contains Sodium Thiosulfate.
Pedmark has a total of 4 drug patents out of which 0 drug patents have expired.
Pedmark was authorised for market use on 20 September, 2022.
Pedmark is available in solution;intravenous dosage forms.
Pedmark can be used as a method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administration of cisplatin.
The generics of Pedmark are possible to be released after 01 July, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2025 |
| Orphan Drug Exclusivity(ODE-384) | Sep 20, 2029 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 20 September, 2022
Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...
Dosage: SOLUTION;INTRAVENOUS
PEDMARK family patents
